-

10:43:07 PM

ZLAB Stock News

ZLAB - Zai Lab Limited

06/03/22 8:00 AM

Nasdaq : ZLAB

clinical trial

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

RHEA-AI

neutral

05/31/22 8:00 AM

Nasdaq : ZLAB

conferences

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy Results showed a significant extension of

RHEA-AI

neutral

05/24/22 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations at June Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following

RHEA-AI

neutral

05/20/22 4:01 PM

Nasdaq : ZLAB

Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19)

RHEA-AI

neutral

05/10/22 4:01 PM

Nasdaq : ZLAB

earnings

Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today

RHEA-AI

positive

05/05/22 11:54 AM

Nasdaq : ZLAB

clinical trial

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease severity - Statistically significant separation from placebo in key

RHEA-AI

neutral

04/28/22 7:30 AM

Nasdaq : ZLAB

clinical trial

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median DOR follow-up of 3.7 months 36-67%

RHEA-AI

neutral

04/21/22 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm

Zai Lab Limited (NASDAQ:

RHEA-AI

positive

04/20/22 7:30 AM

Nasdaq : ZLAB

earnings

Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today

RHEA-AI

neutral

04/19/22 8:00 AM

Nasdaq : ZLAB

Zai Lab Plants a Tree for Every Employee on Earth Day 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today, in

RHEA-AI

very positive

Prev 1 2 3 4 5 6 7 8 9 10 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees1951
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.